Browse studies

Find your next paid study

15 recruiting studies matching your filters

Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation

This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of…

LymphomaRefractory B-Cell LymphomaLymphoma, B-Cell+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT04300998

Phase 1

A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administ…

B Cell LymphomaNHL, AdultMantle Cell Lymphoma+23 more

Estimated

~$150 – $4,200

Phase 1

An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)

Axatilimab + CAR-T in High-Risk Lymphoma

Diffuse Large B Cell Lymphoma (DLBCL)Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma (HGBCL)+3 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Northside Hospital, Inc.NCT07638982

Phase 1

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. T…

Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Paolo Caimi, MDNCT07225439

Phase 1

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or re…

Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Phase 2

Cerebral Spinal Fluid Circulating Tumor DNA (ctDNA) Analysis in Patients With Aggressive B-cell Lymphoma Receiving Front Line Therapy and at High Risk for Central Nervous System Relapse

The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cer…

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaStage III High Grade B-Cell Lymphoma+7 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer Center

Observational

Sequencing-guided cHemotherapy Optimization Using Real-Time Evaluation in Newly Diagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA

The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly d…

LymphomaLymphoma, B-CellDiffuse Large B Cell Lymphoma+2 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Hua-Jay J Cherng, MDNCT06693830

Phase 1

A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side eff…

Non-hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+7 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Marcela V. Maus, M.D.,Ph.D.NCT06026319

Phase 2

A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-…

Large B-cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+4 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Marcela V. Maus, M.D.,Ph.D.NCT06550141

Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I t…

Non-Hodgkin LymphomaT-Cell LymphomaDiffuse Large B-Cell Lymphoma+7 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Natera, Inc.NCT07750886

Phase 1

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unme…

B-Cell Non-Hodgkin's Lymphoma (NHL)Lymphoma, Non-HodgkinsLymphomas Non-Hodgkin's B-Cell+12 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Phase 2

Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual …

Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell Lymphoma+2 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Abramson Cancer Center at Penn MedicineNCT06458439